To the Editor: I read with great interest the recent study performed by Selinger et al. 1 exploring the potential utility of immunohistochemical screening for ALK rearrangements. Although the results of the study are convincingly portrayed, I did note some potential omissions worth pointing out, especially given the major impact that the study might have on the logistical approach that many laboratories might choose to take as part of the very important work-up of non-small-cell lung cancers (NSCLCs). Although the methods outline the origin of the sample, the authors do not elaborate upon any form of a priori sample size calculations. These calculations can be easily performed using web-based tools; alternatively, a number of medically oriented reviews are available explaining the calculations involved. Using the worked examples of Jones et al., 2 given the assumption of ALK rearrangement in 3-4% of cases of NSCLC, 1 and presuming test sensitivity of at least 95% (which is often assumed in sample size calculations for studies of screening tests 2 ), I calculated a minimum sample size of 2086. This suggested that sample size is much larger than that used by Selinger et al. 1 and relates to the very low prevalence of ALK rearrangements in NSCLC.
Another vitally important omission is the complete lack of any statements relating to the statistical quantification of uncertainty (eg, 95% confidence intervals); this violates one of the major tenets of diagnostic testing research, as set out by the STARD group. 3 Admittedly, the lack of any false-negative immunohistochemical results in this study makes accurate calculation of confidence intervals difficult. Nevertheless, estimates are possible: if one uses the online tool provided by the KT-clearinghouse group 4 (with the caveat that a 0 false-negative value be estimated by a small non-zero value, eg, 0.01), the sensitivity in the current study can be estimated at 100% with 95% confidence interval ranging from as low as 64 to 100%. This wide confidence interval also likely relates to undersampling.
A final comment highlighting the importance of follow-up FISH studies pursuant to a positive ALK immunohistochemical result is warranted. Such a statement is an important one in order to ensure that laboratories hoping to optimize their efficiencies not assume that a positive ALK immunohistochemical test equates to a positive ALK rearrangement (especially in light of the very low positive predictive value noted in this study).
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Etienne
All the data required to estimate confidence intervals (CIs) are included in our paper. Using an online tool to estimate CIs 6 based on the data in Table 3 1 if any IHC staining is considered positive (1, 2, or 3 þ intensity, and using 0.001 as a substitute for 0 where required), the D5F3 antibody (and the ALK1 clone) had a sensitivity of 100% (95% CI 64.6-100%), specificity 99.0% (95% CI 97.8-99.5%), negative predictive value 100% (95% CI 99.3-100%), and positive predictive value 53.8% (95% CI 29.1-76.8%). However, as shown in Table 3 , most true positive cases stained only weakly with the ALK1 clone (5 of 7 with 1 þ intensity) compared to the D5F3 clone where most cases stained more strongly (only 2 of 7 with weak 1 þ staining). 5A4 had a sensitivity of 100% (95% CI 64.6-100%), specificity of 98.1% (95% CI 96.7-99.0%), a negative predictive value of 100% (95% CI 99.3-100%), and positive predictive value of 38.9% (95% CI 20.3-61.4%). While this shows that the 95% CIs are relatively wide as a result of the low numbers of ALK FISH-positive cases, the very high negative predictive value of IHC (100% with 95% CI 99.3-100%) supports our conclusion that ALK IHC is a valuable screening method where false negatives are important to avoid. Screening strategies require confirmation by a more accurate testing method and the relatively low positive predictive values support confirmation by FISH testing as outlined in our paper. 1 The optimal diagnostic algorithm to detect ALK in clinical samples is still evolving and will likely be influenced not only by test sensitivity and specificity but also by local expertise and cost effectiveness. Our study and others support the inclusion of IHC within this algorithm. The recently published consensus Molecular Testing Guidelines from CAP/IASLC/ AMP 7 recommend that 'ALK immunohistochemistry, if carefully validated, may be considered as a screening methodology to select specimens for ALK FISH testing.' In addition, the IASLC Atlas of ALK Testing in Lung Cancer 5 states that 'a high diagnostic specificity and sensitivity for ALK IHC' compared to FISH has been confirmed in many studies.' As in our paper, the authors of the ALK Atlas recommend that ALK FISH is used to verify all IHC-positive cases until further data are obtained regarding clinicopathological associations of ALK IHC-positive cases and importantly response to ALK inhibition. 5 Finally, we are in complete agreement that further prospective studies are required to establish the optimal diagnostic strategy for detection of ALK gene rearrangements in NSCLC.
